Castle Biosciences, Inc. (CSTL)
| Market Cap | 511.56M |
| Revenue (ttm) | 98.12M |
| Net Income (ttm) | -51.64M |
| Shares Out | 26.26M |
| EPS (ttm) | -1.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 303,730 |
| Open | 19.54 |
| Previous Close | 19.71 |
| Day's Range | 19.22 - 20.42 |
| 52-Week Range | 17.01 - 78.92 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 66.59 (+241.8%) |
| Earnings Date | May 9, 2022 |
About CSTL
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test...
Financial Performance
In 2021, CSTL's revenue was $94.09 million, an increase of 50.18% compared to the previous year's $62.65 million. Losses were -$31.29 million, 204.3% more than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for CSTL stock is "Buy." The 12-month stock price forecast is 66.59, which is an increase of 241.84% from the latest price.
News
Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences has once again teamed up with The Sun Bus as a national sponsor of their mobile clinic.
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -19.40% and 6.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences Reports First Quarter 2022 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the f...
Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced that it will collaborate with the Melanoma Research Foundation and The Skin Cancer Foundation during Skin Cancer Awareness Month.
Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer P...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced that its current U.S. Federal Supply Schedule contract with the Veterans Health Administration was expanded as of April 15, 2022.
Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for Tissu...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarrettsEsophagus--Castle announced an independent, peer-reviewed article in Clinical Gastroenterology and Hepatology for its TissueCypher® Barrett's Esoph...
Castle Biosciences Completes Acquisition of AltheaDx
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences announced that it has completed its acquisition of AltheaDx, Inc.
Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will release its financial results for the first quarter ended March 31, 2022, after the close of market on Monday, May 9, 2022.
Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Unteste...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data from a recent study showing patients tested with DecisionDx®-Melanoma had improved survival compared to untested patients.
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data on its skin cancer gene expression profile tests at the 18th European Association of Dermato Oncology (EADO) Congress.
Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Ato...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced a poster presentation on its inflammatory skin disease pipeline test at the 4th Annual Revolutionizing Atopic Dermatitis Conference.
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 p.m. ET.
Castle Biosciences to Acquire AltheaDx
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #MA--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a d...
Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett's Esophagus T...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarrettsEsophagus--Castle Biosciences announced that the Centers for Medicare & Medicaid Services granted ADLT status for the TissueCypher® Barrett's Esoph...
Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of Decision...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data on two of its GEP tests for skin cancer at the 2022 American Academy of Dermatology (AAD) Annual Meeting, March 25-29, 2022.
Independent Data Presented at Society for Surgical Oncology Conference Demonstrated DecisionDx®-Melanoma Outperforms ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on DecisionDx®-Melanoma and i31-SLNB at the SSO 2022 International Conference on Surgical Cancer Care, March 9-12.
Castle Biosciences to Present at Upcoming Investor Conferences
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences is scheduled to present a company overview at upcoming investor conferences.
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 41.86% and 6.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarrettsEsophagus--Castle today announced its financial results for the fourth quarter and twelve months ended Dec. 31, 2021.
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q4 Earnings Expected to Decline
Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday,...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the fourth quarter and year-ended Dec. 31, 2021, after the close of market on Monday, Feb. 28, 2022.
Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 11th Annual SVB Leerink Global Healthcare Conference on Feb. 17, 2022, at 3 p.m. ET.
Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEE...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced a collaboration with the NCI to link DecisionDx®-Melanoma testing data with data from the SEER Program's registries.
Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarretsEsophagus--Castle Biosciences announced that it has received a 2022 Top Workplaces USA award from Energage.